Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Andrew L. Laccetti"'
Autor:
Andrew L. Laccetti, Benjamin Garmezy, Lianchun Xiao, Minas Economides, Aradhana Venkatesan, Jianjun Gao, Eric Jonasch, Paul Corn, Amado Zurita‐Saavedra, Landon C. Brown, Chester Kao, Emily N. Kinsey, Rajan T. Gupta, Michael R. Harrison, Andrew J. Armstrong, Daniel J. George, Nizar Tannir, Pavlos Msaouel, Amishi Shah, Tian Zhang, Matthew T. Campbell
Publikováno v:
Cancer Medicine, Vol 10, Iss 7, Pp 2341-2349 (2021)
Abstract Introduction Two separate antiangiogenic tyrosine kinase inhibitors (TKIs) and immunotherapy (IO) combinations are FDA‐approved as front‐line treatment for metastatic renal cell carcinoma (mRCC). Little is known about off‐protocol and
Externí odkaz:
https://doaj.org/article/93fb0ccf60b5470ca6cdd487ce1a82ce
Autor:
Sumit K. Subudhi, Andrew L. Laccetti
Publikováno v:
Current Opinion in Urology. 27:566-571
Metastatic castration-resistant prostate cancer is in critical need of new and innovative treatment strategies. Since the approval of sipuleucel-T, the investigatory climate of prostate cancer immunotherapy has been rapidly evolving with promising de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e77c0c4aa6083580e9956cc4e605cd67
https://doi.org/10.1097/mou.0000000000000433
https://doi.org/10.1097/mou.0000000000000433
Publikováno v:
British Journal of Cancer
Background: Early-stage lung cancer represents a key focus of numerous multicenter clinical trials, but common exclusion criteria such as a prior cancer diagnosis may limit enrollment. We examined the prevalence and prognostic impact of a prior cance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3983a61b121a595471199ef6dcdc637e
http://europepmc.org/articles/PMC5355931
http://europepmc.org/articles/PMC5355931
Autor:
Beibei Chen, Simon J. Craddock Lee, Yang Xie, Samantha Gates, Andrew L. Laccetti, Jennifer Cai, David E. Gerber
Publikováno v:
Journal of Oncology Practice. 12:e981-e990
Purpose: Electronic portals provide patients with real-time access to personal health records. Use of this technology by individuals with cancer is particularly intensive. We therefore examined patterns of use of electronic portals by clinic staff at
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebade1b853aafb7b5365328a6b5f7d29
https://doi.org/10.1200/jop.2016.011817
https://doi.org/10.1200/jop.2016.011817
Autor:
David H. Aggen, Ying-Bei Chen, Chloe Dadoun, Colette Owens, Robert A. Lefkowitz, Robert J. Motzer, Darren R. Feldman, Deaglan Joseph McHugh, Martin H. Voss, Maria I. Carlo, Neil J. Shah, Andrew L. Laccetti, Andrea Knezevic, Eduard Reznik, Ritesh Kotecha, Chung-Han Lee, Diana Tassone, Natalie Shapnik
Publikováno v:
Journal of Clinical Oncology. 39:4509-4509
4509 Background: Cabozantinib plus nivolumab (CaboNivo) improved objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) over sunitinib in a phase 3 trial for metastatic clear cell renal cell carcinoma (RCC). (Chouei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cee21e6b931ffe4e7946baff39139202
https://doi.org/10.1200/jco.2021.39.15_suppl.4509
https://doi.org/10.1200/jco.2021.39.15_suppl.4509
Autor:
Sarah Brown, Alyssa G. Rieber, Hilary Y. Ma, Andrew James Wiele, Sarah Rizvi, Leslie Stapleton, Anne Park, Helen Ajufo, Andrew L. Laccetti, Joshua Michael Gulvin
Publikováno v:
Journal of Clinical Oncology. 37:60-60
60 Background: Treatment for biochemically recurrent (bcr) and metastatic prostate cancer (pc) is evolving, making multidisciplinary evaluation a critical need. Our center, a community public hospital, lacked clear referral criteria between the Urolo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::83a4cddfbd29a1c4f01e57d884c5fe7c
https://doi.org/10.1200/jco.2019.37.27_suppl.60
https://doi.org/10.1200/jco.2019.37.27_suppl.60
Autor:
Michael VanAlstine, Nipa Sheth, Andrew L. Laccetti, Christopher J. Logothetis, Rebecca S. S. Tidwell
Publikováno v:
Journal of Clinical Oncology. 37:e18068-e18068
e18068 Background: Wearable activity trackers and frequent interrogation of remote patient reported outcomes (PROs) have the potential to revolutionize oncology clinical trial design, therapeutic sequencing and patient (pt) safety. Established feasib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e624e932ce671cf810772deda34a2682
https://doi.org/10.1200/jco.2019.37.15_suppl.e18068
https://doi.org/10.1200/jco.2019.37.15_suppl.e18068
Autor:
Aradhana M. Venkatesan, Pavlos Msaouel, Nizar M. Tannir, Jianjun Gao, Eric Jonasch, Paul G. Corn, Amishi Yogesh Shah, Matthew T. Campbell, Amado J. Zurita, Minas P. Economides, Andrew L. Laccetti
Publikováno v:
Journal of Clinical Oncology. 37:630-630
630 Background: Emerging phase III data support combination antiangiogenic tyrosine kinase inhibitors (TKIs) and immunotherapy (IO) as front line treatment for metastatic renal cell carcinoma (mRCC). Little is known about off-protocol experience and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7afcf6a2935afc05c804799e85e100e8
https://doi.org/10.1200/jco.2019.37.7_suppl.630
https://doi.org/10.1200/jco.2019.37.7_suppl.630
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 98
Introduction Management of locally advanced non-small cell lung cancer is among the most highly contested areas in thoracic oncology. In this population, a history of prior cancer frequently results in exclusion from clinical trials and may influence
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::547fd62ed29c92a06381b265e4a3b416
https://pubmed.ncbi.nlm.nih.gov/27393515
https://pubmed.ncbi.nlm.nih.gov/27393515
Publikováno v:
Journal of the National Cancer Institute. 107(4)
Fewer than 5% of adults with cancer in the United States participate in clinical trials (1–4). Low accrual rates prolong study duration, limit generalizability, lead to premature study termination, limit the number of patients exposed to potentiall
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8844d5121a56d7cfb54b4faaaf31a4c4
https://pubmed.ncbi.nlm.nih.gov/25667420
https://pubmed.ncbi.nlm.nih.gov/25667420